Canaccord Genuity Maintains Buy on Cytokinetics (CYTK)

November 1, 2012 12:34 PM EDT Send to a Friend
Get Alerts CYTK Hot Sheet
Price: $4.59 +4.32%

Rating Summary:
    7 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 12 | New: 23
Trade CYTK Now!
Join SI Premium – FREE
Canaccord Genuity maintained a Buy rating on Cytokinetics (NASDAQ: CYTK) and lowered its price target to $4.00 (from $6.00).

"We think CK357 (tirasemtiv) Ph1/2 proof-of-concept data in ALS shows unique if early efficacy potential. We also think partner Amgen is committed to developing omecamtiv for heart failure," said analyst Ritu Baral.

For an analyst ratings summary and ratings history on Cytokinetics click here. For more ratings news on Cytokinetics click here.

Shares of Cytokinetics closed at $0.68 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment